Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

14.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
14.7K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

15.9K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.9K
T Cell Types and Functions01:24

T Cell Types and Functions

2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

2.9K
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
2.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

IgG Subclass (IgG1-4) and IgA Autoantibody Profiles Against Muscle-Specific Kinase in a Greek Cohort.

Muscle & nerve·2026
Same author

Building Towards Initiation, Moderation, De-Escalation and Cessation of Disease-Modifying Treatments for Multiple Sclerosis in Greece: An Expert Panel Consensus Meeting.

Brain sciences·2026
Same author

Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Spinal H-Sign in Syphilitic Myelitis Mimicking MOGAD.

The neurologist·2026
Same author

Generation of Monoclonal Autoantibodies From Myelin Oligodendrocyte Glycoprotein-Specific Human B Cells Using an Optofluidic-Based Platform.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Failure of early B cell tolerance and possible BCR signaling dysregulation underlie NF155-mediated autoimmune nodopathies.

Proceedings of the National Academy of Sciences of the United States of America·2026

相关实验视频

Updated: Jan 13, 2026

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

11.1K

在多发性硬化症和过渡性CD52枯竭中,B细胞耐受性检查点的功能.

Anastasia Alexaki1, Fotis Baltoumas2, Dimitrios Tzanetakos3

  • 1First Department of Neurology, National and Kapodistrian University of Athens, Greece.

Journal of neuroimmunology
|January 8, 2026
PubMed
概括

对多发性硬化症的阿莱姆图祖马布治疗没有改变B细胞耐受性检查点. 继发性自身免疫风险与B细胞自动反应在阿勒姆图祖马布 (抗CD52) 治疗后没有联系.

关键词:
艾伦图祖马布 (Alemtuzumab) 是一种药物.B细胞的耐受性CD52 CD52 CD52 CD52 的意思是什么意思?多发性硬化症是多发性硬化症.

更多相关视频

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.8K
Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier
09:00

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier

Published on: April 5, 2017

20.8K

相关实验视频

Last Updated: Jan 13, 2026

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
09:51

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells

Published on: May 18, 2018

11.1K
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

14.8K
Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier
09:00

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier

Published on: April 5, 2017

20.8K

科学领域:

  • 免疫学 免疫学 免疫学
  • 神经免疫学 神经免疫学
  • 这是一种自身免疫力.

背景情况:

  • 阿拉姆图祖马布 (抗CD52) 有效治疗复发性复发性多发性硬化症 (MS).
  • 阿拉姆图祖马布可以引起二次自身免疫,但其对B细胞耐受性的影响尚不清楚.
  • 了解B细胞耐受性对于管理多发性硬化及其治疗至关重要.

研究的目的:

  • 为了评估外围B细胞耐受性检查点的完整性,在阿勒姆图祖马布治疗的多发性硬化症患者中.
  • 为了研究B细胞自身反应性和二次自身免疫力在阿莱姆图祖马布后的关系.
  • 分析与耐受性机制相关的B细胞受体 (BCR) 谱系参数.

主要方法:

  • 从单个成熟的原始B细胞中构建了138个重组单克隆抗体 (mAbs).
  • 在健康捐赠者 (HDs),免疫治疗前的多发性硬化症患者和接受过阿勒姆图祖马布治疗的多发性硬化症患者中测试了多重和自动反应的mAbs.
  • 分析的B细胞受体 (BCR) 谱系参数,包括互补性决定区域3 (CDR3) 净负荷.

主要成果:

  • 两组之间没有发现多活性和自身活性B细胞分数的显著差异.
  • 自主反应性B细胞分量与二次自身免疫或未来MS活动没有相关性.
  • 与HD患者相比,Alemtuzumab治疗的患者的平均原始CDR3净电荷较低,这是一个孤立的发现.

结论:

  • 过渡性CD52耗尽与阿勒姆图祖马布似乎没有显著改变外围B细胞耐受性检查点.
  • 二次性自身免疫风险不太可能与治疗后B细胞自身活性的重大变化直接相关.
  • 结果可能会为MS和相关疾病的其他免疫复合疗法提供信息.